Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro; Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

Taking stock of the drug industry, from the lab to the medicine chest

October 20, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Darron Cummings/AP STAT+ | Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro The Mounjaro complaint was made one month after Lilly filed related lawsuits against compounding pharmacies, spas, and wellness centers. By Ed Silverman STAT+ | Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion The two companies will partner on three targeted chemotherapy treatments, known as antibody-drug conjugates. By Andrew Joseph STAT+ | Study on Amgen's 'bispecific' immunotherapy could lead to approval in small cell lung cancer The drug generated strong response rates in patients with advanced small cell lung cancer, results that could lead to approval. By Andrew Joseph Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser